Showing results (61-70 of 2,810) with videos related to
Sort By:
Pageof 281
Expert Opinion on Drug Safety|December 17, 2024
Adverse events of nusinersen: a real-world drug safety surveillance study based on the FDA adverse event reporting system (FAERS) databaseXiaofang Zhang, Jianxiong Gui, Lingman Wang, et al.Expert Opinion on Drug Safety|December 16, 2024
Epidemiological investigation of adult emergency infusion adverse drug reactions (EIADR) in Nanjing, China: a prospective cross-sectional study (EIADR II)Gen Ba, Weiwen Hao, Qifang Shi, et al.Expert Opinion on Drug Safety|December 13, 2024
A 13-years pharmacovigilance analysis of novel hormonal agents in prostate cancer using the FDA adverse event reporting system databaseHaiwei Xiao, Tao Qin, Yanping Wen, et al.Expert Opinion on Drug Safety|December 23, 2024
Fulminant type 1 diabetes mellitus: a neglected but high-risk adverse event associated with immune checkpoint inhibitorsKelin Meng, Shengling Fu, Yaochen Huang, et al.Expert Opinion on Drug Safety|December 24, 2024
Adverse events in patients with castration-resistant prostate cancer treated with ra-223: a retrospective pharmacovigilance studyLei Yang, Guoqiang Zeng, Yuantao Wang, et al.Expert Opinion on Drug Safety|December 23, 2024
Detection of risk signals for ustekinumab in the real world using the FDA Adverse Event Reporting System (FAERS)Yi Zhao, Zelin Li, Kanghuai Zhang, et al.Expert Opinion on Drug Safety|December 24, 2024
Safety and efficacy of pharmacotherapies for pelvic inflammatory disease and endometriosisSimone Ferrero, Umberto Leone Roberti Maggiore, Michele Paudice, et al.Expert Opinion on Drug Safety|December 21, 2024
Adverse event of ruxolitinib cream: a real-world analysis based on FDA Adverse Event Reporting System from 2021 to 2024Shu Zhou, Li Lei, Ling Jiang, et al.Expert Opinion on Drug Safety|December 17, 2024
Real-world study of isavuconazole adverse events based on pharmacovigilance spontaneous reporting systemsNannan Ding, Ji Zhang, Dan Yang, et al.Expert Opinion on Drug Safety|December 17, 2024
Identification of risk factors for gastrointestinal immune-related adverse events associated with immune check point inhibitorsRyo Morikawa, Kentaro Nitta, Shuntaro Yasuda, et al.Pageof 281